Skip to main content

Volume 19 Supplement 1

Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts

Meeting abstracts

Publication of this supplement has not been supported by sponsorship. Some Supplement Editors declare potential competing interest, as follow: Paolo A. Ascierto (Consulting fee: BMS, Roche, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Newlinks Genetics, Genmab, Medimmune, Sindax, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore - Contracted Research: BMS, Roche, Array - Travel support: MSD) - Carlo Bifulco (Consultant/advisory relationship: PrimeVax, BMS, Ventana, HalioDx; Stock Ownership: PrimeVax; Patent US20180322632A1: Image processing systems and methods for displaying multiple images of a biological specimen) - Sandra Demaria (grant to Institution from Lytix Biopharma and Nanobiotix, honorarium for advisory/consulting from Lytix Biopharma, Ono Pharmaceutical, and EMD Serono) - Patrick Hwu (Scientific Advisory Board: Immatics, Dragonfly) - Igor Puzanov (consulting: Amgen, Merck, Iovance).

Virtual2-5 December 2020

Conference website 

Edited by Paolo A. Ascierto, Carlo Bifulco, Sandra Demaria, Reinhard Dummer, Patrick Hwu, Francesco Marincola, Giuseppe Masucci, Iman Osman, Igor Puzanov.

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    6.9 - 5-year Impact Factor
    1.458 - SNIP (Source Normalized Impact per Paper)
    1.544 - SJR (SCImago Journal Rank)

    2022 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    84 days submission to accept (Median)

    2022 Usage 
    32,614 Altmetric mentions